1800-272-662
Shopping Cart 0
countryflagAU
Login

Recce Pharmaceuticals Ltd

Healthcare AU RCE

0.475AUD
0.03(6.74%)

Last update at 2026-03-13T05:10:00Z

Day Range

0.460.47
LowHigh

52 Week Range

0.280.73
LowHigh

Fundamentals

  • Previous Close 0.45
  • Market Cap128.69M
  • Volume56361
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-28.99235M
  • Revenue TTM0.97M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM -11.18001M
  • Diluted EPS TTM-0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -21.42809M -22.56772M -13.07742M -10.98628M -13.51337M
Minority interest - - - - -
Net income -21.42809M -17.66171M -13.07742M -10.98869M -15.10834M
Selling general administrative 8.46M 5.87M 4.11M 2.37M 6.81M
Selling and marketing expenses 1.24M 1.24M 1.12M 0.99M 0.70M
Gross profit -2.93749M -2.18818M - - -
Reconciled depreciation 0.36M 0.37M 0.22M 0.19M 0.30M
Ebit -20.40648M -21.72087M -12.90480M -10.98386M -13.51126M
Ebitda -20.33463M -21.35411M -12.68764M -10.79619M -13.21563M
Depreciation and amortization 0.07M 0.37M 0.22M 0.19M 0.30M
Non operating income net other - - - - -
Operating income -22.88044M -22.05124M -12.90480M -10.98386M -13.51126M
Other operating expenses 30.39M 21.37M 17.24M 12.60M 15.20M
Interest expense 1.26M 0.85M 0.17M 0.00242M 0.00211M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.11M 0.19M 0.18M 0.09M 0.11M
Net interest income -1.15316M -0.65985M -0.11707M 0.08M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.73827M -4.90601M 4.45M 0.00242M 1.59M
Total revenue 7.51M 5.03M 4.43M 3.18M 1.96M
Total operating expenses 19.94M 21.68M 17.24M 12.60M 15.20M
Cost of revenue 10.45M 7.22M - - -
Total other income expense net 1.45M -0.51649M 4.28M -0.00242M -0.00211M
Discontinued operations - - - - -
Net income from continuing ops -21.42809M -17.66171M -13.07742M -10.98628M -13.51337M
Net income applicable to common shares -21.42809M -17.66171M -13.07742M -10.98628M -13.51337M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 12.41M 6.37M 2.56M 12.62M 21.68M
Intangible assets - - 0.00002M 0.00003M 0.00006M
Earning assets - - - - -
Other current assets 0.21M 0.56M 0.16M 0.42M 0.06M
Total liab 15.47M 15.89M 5.14M 2.56M 1.18M
Total stockholder equity -3.05200M -9.52377M -2.58880M 10.06M 20.50M
Deferred long term liab - - - - -
Other current liab - 10.88M 3.90M 1.97M 0.59M
Common stock - 54.84M 44.11M 43.97M 43.30M
Capital stock 81.50M 54.84M 44.11M 43.97M 43.30M
Retained earnings -91.50396M -70.07587M -55.53532M -42.45790M -31.47162M
Other liab - - 0.19M 0.12M 0.09M
Good will - - - - -
Other assets - - - - -
Cash 10.45M 4.21M 1.56M 11.58M 20.87M
Cash and equivalents - - - - -
Total current liabilities 6.13M 15.07M 4.85M 2.45M 1.08M
Current deferred revenue - - -0.14788M -0.07476M -0.11259M
Net debt - -3.39613M -1.31101M -11.50717M -20.74609M
Short term debt - 0.22M 0.15M 0.07M 0.11M
Short long term debt 1.53M - - - -
Short long term debt total - 0.81M 0.25M 0.07M 0.13M
Other stockholder equity - - 8.83M -1.51042M -11.82568M
Property plant equipment - - 0.61M 0.44M 0.50M
Total current assets 11.39M 5.14M 1.95M 12.18M 21.18M
Long term investments - - - - -
Net tangible assets - - -2.58882M 10.06M 20.50M
Short term investments - 0.21M 0.05M 0.02M -
Net receivables - 0.16M 0.09M 0.18M 0.25M
Long term debt 8.60M - - - -
Inventory - - 0.14M - -
Accounts payable 2.18M 3.97M 0.95M 0.48M 0.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 5.71M 8.83M 8.55M 8.68M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00000M -0.00002M -0.00003M -0.00006M
Deferred long term asset charges - - - - -
Non current assets total 1.03M 1.23M 0.61M 0.44M 0.50M
Capital lease obligations 0.64M 0.81M 0.25M 0.07M 0.13M
Long term debt total - - 0.10M 0.00000M 0.01M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.44390M -0.14189M -0.03863M -0.04034M -0.07601M
Change to liabilities - - 0.77M 0.16M 0.28M
Total cashflows from investing activities -0.44390M -0.14189M -0.03863M -0.04034M -0.07601M
Net borrowings 0.59M 5.89M 2.71M -0.13917M -0.17470M
Total cash from financing activities 26.92M 16.00M 2.71M -0.24050M 26.12M
Change to operating activities - - -1.01017M 1.31M 0.06M
Net income -21.42809M -17.66171M -13.07742M -10.98628M -13.51337M
Change in cash 6.03M 2.85M -10.02036M -9.29111M 18.19M
Begin period cash flow 4.42M 1.56M 11.58M 20.87M 2.68M
End period cash flow 10.45M 4.42M 1.56M 11.58M 20.87M
Total cash from operating activities -20.44210M -13.00866M -12.68737M -9.01026M -7.85585M
Issuance of capital stock 28.35M 11.15M 0.10M 0.29M 28.06M
Depreciation - 0.37M 0.22M 0.19M 0.30M
Other cashflows from investing activities -0.18092M - - - -
Dividends paid - - - 1.72M 1.72M
Change to inventory - - 0.24M -1.46884M 0.00000M
Change to account receivables 0.28M 0.06M 0.09M 0.06M -0.20412M
Sale purchase of stock - - 0.10M -1.71867M -1.71867M
Other cashflows from financing activities -2.02191M -1.02761M -0.27450M -0.38873M -0.04019M
Change to netincome - - 0.33M 0.26M 5.22M
Capital expenditures 0.03M 0.14M 0.04M 0.04M 0.08M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.70707M 4.27M -0.15232M 1.53M 0.14M
Stock based compensation - 0.02M 0.33M 0.26M 5.22M
Other non cash items -19.73503M 0.39M -0.09832M 0.46M 5.73M
Free cash flow -20.46845M -13.15055M -12.72600M -9.05061M -7.93186M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RCE
Recce Pharmaceuticals Ltd		 0.03 6.74% 0.47 - - 132.05 183.30 -8.4268
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. The company has strategic partnership with Murdoch Children's Research Institute for development of the Acinetobacter baumannii and Mycobacterium abscessus; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Recce Pharmaceuticals Ltd

Governor Macquarie Tower, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. James Hamilton-Bray Graham GAICD CEO, MD & Exec. Director NA
Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) Chief Scientific Director & Exec. Director NA
Dr. Justin Ward Principal Quality Chemist & Exec. Director NA
Mr. Arthur Kollaras Principal Engineer & Head of Manufacturing NA
Mr. Justin Reynolds Chief Financial Officer NA
Thomas Jarrett Operations Mang. NA
Mr. Daniel Astudillo B.A., B.Com., M.B.A. Head of Marketing NA
Ms. Maggie Niewidok Company Sec. NA
Dr. John K. A. Prendergast Ph.D. Executive Chairman of the Board 1954
Mr. James Hamilton-Bray Graham GAICD CEO, MD & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.